173 related articles for article (PubMed ID: 2245488)
1. Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes.
Bally MB; Nayar R; Masin D; Cullis PR; Mayer LD
Cancer Chemother Pharmacol; 1990; 27(1):13-9. PubMed ID: 2245488
[TBL] [Abstract][Full Text] [Related]
2. Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice.
Bally MB; Masin D; Nayar R; Cullis PR; Mayer LD
Cancer Chemother Pharmacol; 1994; 34(2):137-46. PubMed ID: 8194164
[TBL] [Abstract][Full Text] [Related]
3. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.
Mayer LD; Tai LC; Ko DS; Masin D; Ginsberg RS; Cullis PR; Bally MB
Cancer Res; 1989 Nov; 49(21):5922-30. PubMed ID: 2790807
[TBL] [Abstract][Full Text] [Related]
4. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes.
Harasym TO; Cullis PR; Bally MB
Cancer Chemother Pharmacol; 1997; 40(4):309-17. PubMed ID: 9225948
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes.
Rahman A; White G; More N; Schein PS
Cancer Res; 1985 Feb; 45(2):796-803. PubMed ID: 3967247
[TBL] [Abstract][Full Text] [Related]
6. Liposomes with entrapped doxorubicin exhibit extended blood residence times.
Bally MB; Nayar R; Masin D; Hope MJ; Cullis PR; Mayer LD
Biochim Biophys Acta; 1990 Mar; 1023(1):133-9. PubMed ID: 2317492
[TBL] [Abstract][Full Text] [Related]
7. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin.
Krishna R; St-Louis M; Mayer LD
Int J Cancer; 2000 Jan; 85(1):131-41. PubMed ID: 10585596
[TBL] [Abstract][Full Text] [Related]
8. Increased bone marrow toxicity of doxorubicin bound to nanoparticles.
Gibaud S; Andreux JP; Weingarten C; Renard M; Couvreur P
Eur J Cancer; 1994; 30A(6):820-6. PubMed ID: 7917543
[TBL] [Abstract][Full Text] [Related]
9. Comparative immunotoxicity of free doxorubicin and doxorubicin encapsulated in cardiolipin liposomes.
Rahman A; Ganjei A; Neefe JR
Cancer Chemother Pharmacol; 1986; 16(1):28-34. PubMed ID: 3484382
[TBL] [Abstract][Full Text] [Related]
10. Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model.
Storm G; Roerdink FH; Steerenberg PA; de Jong WH; Crommelin DJ
Cancer Res; 1987 Jul; 47(13):3366-72. PubMed ID: 3581073
[TBL] [Abstract][Full Text] [Related]
11. Enhanced tumor targeting of doxorubicin by ganglioside GM1-bearing long-circulating liposomes.
Unezaki S; Maruyama K; Ishida O; Takahashi N; Iwatsuru M
J Drug Target; 1993; 1(4):287-92. PubMed ID: 8069570
[TBL] [Abstract][Full Text] [Related]
12. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone.
Lim HJ; Masin D; Madden TD; Bally MB
J Pharmacol Exp Ther; 1997 Apr; 281(1):566-73. PubMed ID: 9103545
[TBL] [Abstract][Full Text] [Related]
13. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
[TBL] [Abstract][Full Text] [Related]
14. An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation.
Gokhale PC; Radhakrishnan B; Husain SR; Abernethy DR; Sacher R; Dritschilo A; Rahman A
Br J Cancer; 1996 Jul; 74(1):43-8. PubMed ID: 8679456
[TBL] [Abstract][Full Text] [Related]
15. Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation.
Mayer LD; Reamer J; Bally MB
J Pharm Sci; 1999 Jan; 88(1):96-102. PubMed ID: 9874708
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
Hong RL; Tseng YL
Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
[TBL] [Abstract][Full Text] [Related]
17. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
Krishna R; Mayer LD
Cancer Res; 1997 Dec; 57(23):5246-53. PubMed ID: 9393743
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).
Parr MJ; Masin D; Cullis PR; Bally MB
J Pharmacol Exp Ther; 1997 Mar; 280(3):1319-27. PubMed ID: 9067319
[TBL] [Abstract][Full Text] [Related]
19. Formation of transition metal-doxorubicin complexes inside liposomes.
Abraham SA; Edwards K; Karlsson G; MacIntosh S; Mayer LD; McKenzie C; Bally MB
Biochim Biophys Acta; 2002 Sep; 1565(1):41-54. PubMed ID: 12225851
[TBL] [Abstract][Full Text] [Related]
20. Effects of intraperitoneal administration of free and liposome-entrapped doxorubicin on rat peritoneal exudate cell populations.
Storm G; Steerenberg PA; Van Borssum Waalkes M; Crommelin DJ
J Drug Target; 1996; 4(4):255-64. PubMed ID: 9010815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
